BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mulder TAM, de With M, Del Re M, Danesi R, Mathijssen RHJ, van Schaik RHN. Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy. Cancers (Basel) 2021;13:771. [PMID: 33673305 DOI: 10.3390/cancers13040771] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Crucitta S, Cucchiara F, Mathijssen R, Mateo J, Jager A, Joosse A, Passaro A, Attili I, Petrini I, van Schaik R, Danesi R, Del Re M. Treatment-driven tumour heterogeneity and drug resistance: lessons from solid tumours. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102340] [Reference Citation Analysis]
2 Luzum JA, Petry N, Taylor AK, Van Driest SL, Dunnenberger HM, Cavallari LH. Moving Pharmacogenetics Into Practice: It's All About the Evidence! Clin Pharmacol Ther 2021. [PMID: 34101169 DOI: 10.1002/cpt.2327] [Reference Citation Analysis]
3 Mulder TAM, van Eerden RAG, de With M, Elens L, Hesselink DA, Matic M, Bins S, Mathijssen RHJ, van Schaik RHN. CYP3A422 Genotyping in Clinical Practice: Ready for Implementation? Front Genet 2021;12:711943. [PMID: 34306041 DOI: 10.3389/fgene.2021.711943] [Reference Citation Analysis]
4 Braal CL, Jager A, Hoop EO, Westenberg JD, Lommen KMWT, de Bruijn P, Vastbinder MB, van Rossum-Schornagel QC, Thijs-Visser MF, van Alphen RJ, Struik LEM, Zuetenhorst HJM, Mathijssen RHJ, Koolen SLW. Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer. Clin Pharmacokinet 2021. [PMID: 34786650 DOI: 10.1007/s40262-021-01077-z] [Reference Citation Analysis]
5 Maillard M, Louveau B, Vilquin P, Goldwirt L, Thomas F, Mourah S. Pharmacogenomics in solid cancers and hematologic malignancies: Improving personalized drug prescription. Therapie 2021:S0040-5957(21)00241-9. [PMID: 34922740 DOI: 10.1016/j.therap.2021.11.003] [Reference Citation Analysis]
6 Marchocki Z, Tone A, Virtanen C, de Borja R, Clarke B, Brown T, May T. Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma. J Ovarian Res 2022;15. [DOI: 10.1186/s13048-022-00983-5] [Reference Citation Analysis]